Xenon Pharmaceuticals Reports Side Effects For Bread-And-Butter Drug; Biotech Stock Crashes | Investor's Business DailySectionsMy IBDMy ProductsRecently SearchedTechnologyLicensingALLISON GATLINUpdated 09:56 AM ET 09/18/2026Xenon Pharmaceuticals (XENE) voluntarily halted enrollment in a handful of studies Friday due to several unexpected side effects. The biotech stock crashed to a six-month low. The drug at the center of the debacle is azetukalner, which Xenon is hoping will soon gain approval to treat epilepsy. Xenon stock shot 50% higher on March 9 following positive results for azetukalner…Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8INVESTING RESOURCESTake a Trial TodayGet instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!IBD VideosGet market updates, educational videos, webinars, and stock analysis.Get StartedLearn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content. ]]>